[go: up one dir, main page]

MX2019001581A - Inhibidores de ssao de aminopirimidina. - Google Patents

Inhibidores de ssao de aminopirimidina.

Info

Publication number
MX2019001581A
MX2019001581A MX2019001581A MX2019001581A MX2019001581A MX 2019001581 A MX2019001581 A MX 2019001581A MX 2019001581 A MX2019001581 A MX 2019001581A MX 2019001581 A MX2019001581 A MX 2019001581A MX 2019001581 A MX2019001581 A MX 2019001581A
Authority
MX
Mexico
Prior art keywords
aminopyrimidine
ssao inhibitors
compounds
ssao
inhibitors
Prior art date
Application number
MX2019001581A
Other languages
English (en)
Other versions
MX389672B (es
Inventor
Andrew Coates David
Zhou Jingye
Heng Qin Luo
Wei Yi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2019001581A publication Critical patent/MX2019001581A/es
Publication of MX389672B publication Critical patent/MX389672B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la Fórmula a continuación, o una sal farmacéuticamente aceptable de estos (ver formula), donde n y R1 se definen en la presente, métodos para tratar pacientes para la enfermedad hepática, y procesos para preparar los compuestos.
MX2019001581A 2016-08-12 2017-08-04 Inhibidores de ssao de aminopirimidina MX389672B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2016/094833 WO2018027892A1 (en) 2016-08-12 2016-08-12 Amino pyrimidine ssao inhibitors
PCT/CN2017/095999 WO2018028517A1 (en) 2016-08-12 2017-08-04 Amino pyrimidine ssao inhibitors

Publications (2)

Publication Number Publication Date
MX2019001581A true MX2019001581A (es) 2019-06-20
MX389672B MX389672B (es) 2025-03-20

Family

ID=61161335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001581A MX389672B (es) 2016-08-12 2017-08-04 Inhibidores de ssao de aminopirimidina

Country Status (22)

Country Link
US (3) US10287270B2 (es)
EP (3) EP4501323A3 (es)
JP (2) JP7035013B2 (es)
KR (3) KR102483876B1 (es)
CN (2) CN108884056B (es)
AU (2) AU2017309199B2 (es)
CA (1) CA3033687A1 (es)
CR (1) CR20190124A (es)
DK (2) DK3984996T3 (es)
ES (2) ES2908805T3 (es)
HU (1) HUE058142T2 (es)
IL (1) IL264745B (es)
MA (1) MA45937A (es)
MX (1) MX389672B (es)
MY (1) MY196576A (es)
NZ (1) NZ750290A (es)
PH (1) PH12019500296A1 (es)
PL (2) PL3497086T3 (es)
PT (1) PT3497086T (es)
SG (1) SG11201900844UA (es)
WO (2) WO2018027892A1 (es)
ZA (2) ZA201901097B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
CN109810041B (zh) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
DK3853234T3 (da) 2018-09-18 2025-07-21 Nikang Therapeutics Inc Fusionerede tricykliske ringderivater som src-homologi-2-fosfatasehæmmere
CN110938059A (zh) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) * 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
HRP20231608T1 (hr) * 2018-10-29 2024-03-15 Boehringer Ingelheim International Gmbh Derivati piridinil sulfonamida, njihovi farmaceutski pripravci i njihove uporabe
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
TWI835945B (zh) * 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
PE20212155A1 (es) * 2019-01-11 2021-11-09 Transthera Sciences Nanjing Inc Compuestos de halo-alilamina y uso de los mismos
US12528791B2 (en) 2019-08-23 2026-01-20 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CA3155114A1 (en) 2019-10-29 2021-05-06 Eccogene (Shanghai) Co., Ltd. Semicarbazide-sensitive amino oxidase inhibitors and use thereof
CN113149957A (zh) * 2020-01-23 2021-07-23 轶诺(浙江)药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
EP4125968A4 (en) * 2020-03-25 2024-04-10 Terns, Inc. TREATMENT OF RESPIRATORY DISEASES
IL298145A (en) * 2020-05-13 2023-01-01 Terns Pharmaceuticals Inc Combined treatment of liver disorders
MX2023002308A (es) * 2020-08-25 2023-07-11 Lilly Co Eli Polimorfos de un inhibidor de ssao.
CN114621243B (zh) * 2020-12-14 2024-03-01 上海拓界生物医药科技有限公司 一种磺酰胺类衍生物及其用途
KR20220145981A (ko) 2021-04-22 2022-11-01 주식회사유한양행 트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물
TW202333726A (zh) * 2021-11-11 2023-09-01 美商拓臻製藥公司 以ssao抑制劑治療肝病
EP4429665A1 (en) * 2021-11-11 2024-09-18 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004166A2 (en) * 2006-03-31 2008-12-24 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
WO2008123469A1 (ja) * 2007-03-30 2008-10-16 Japan Tobacco Inc. 6員環アミド化合物およびその用途
WO2009012573A1 (en) 2007-07-20 2009-01-29 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2008327615B2 (en) 2007-11-21 2014-08-21 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
JP2011136942A (ja) * 2009-12-28 2011-07-14 Kowa Co 新規な置換ピリミジン誘導体およびこれを含有する医薬
LT3002278T (lt) 2011-03-15 2017-06-26 Astellas Pharma Inc. Guanidino junginys
BR112014027406B1 (pt) 2012-05-02 2020-09-24 Boehringer Ingelheim International Gmbh Composto, composição e uso de um composto
MX2015006038A (es) * 2012-11-16 2015-08-07 Squibb Bristol Myers Co Moduladores de pirrolidina del receptor acoplado a la proteina g (gpr40).
US8962641B2 (en) * 2013-04-17 2015-02-24 Boehringer Ingelheim International Gmbh Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
WO2014184104A1 (en) * 2013-05-17 2014-11-20 Boehringer Ingelheim International Gmbh Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors

Also Published As

Publication number Publication date
CN114380801A (zh) 2022-04-22
KR20230008889A (ko) 2023-01-16
SG11201900844UA (en) 2019-02-27
EP3984996A1 (en) 2022-04-20
DK3984996T3 (da) 2024-10-21
MA45937A (fr) 2019-06-19
HUE058142T2 (hu) 2022-07-28
NZ750290A (en) 2022-09-30
US10287270B2 (en) 2019-05-14
CN108884056B (zh) 2022-01-07
US20200262817A1 (en) 2020-08-20
MY196576A (en) 2023-04-19
EP3497086A4 (en) 2020-03-25
US20190276436A1 (en) 2019-09-12
ZA202202097B (en) 2023-11-29
US20180297987A1 (en) 2018-10-18
WO2018028517A1 (en) 2018-02-15
ES2908805T3 (es) 2022-05-04
PL3984996T3 (pl) 2025-03-10
US10793552B2 (en) 2020-10-06
US10464928B2 (en) 2019-11-05
MX389672B (es) 2025-03-20
KR102483876B1 (ko) 2023-01-03
PT3497086T (pt) 2022-03-14
PL3497086T3 (pl) 2022-05-02
JP7372957B2 (ja) 2023-11-01
IL264745B (en) 2021-08-31
JP2022003049A (ja) 2022-01-11
ZA201901097B (en) 2022-08-31
AU2022203071B2 (en) 2024-06-20
JP7035013B2 (ja) 2022-03-14
AU2022203071A1 (en) 2022-05-26
ES2992165T3 (es) 2024-12-09
KR102646063B1 (ko) 2024-03-12
CA3033687A1 (en) 2018-02-15
DK3497086T3 (da) 2022-03-14
EP3497086A1 (en) 2019-06-19
EP3497086B1 (en) 2021-12-15
PH12019500296A1 (en) 2019-05-15
WO2018027892A1 (en) 2018-02-15
EP4501323A2 (en) 2025-02-05
CR20190124A (es) 2019-05-13
EP3984996B1 (en) 2024-10-09
KR20240035917A (ko) 2024-03-18
AU2017309199B2 (en) 2022-05-12
JP2019527717A (ja) 2019-10-03
AU2017309199A1 (en) 2019-02-21
EP4501323A3 (en) 2025-03-19
KR20190038580A (ko) 2019-04-08
BR112019002275A2 (pt) 2019-06-18
CN114380801B (zh) 2025-07-29
CN108884056A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
MX2019001581A (es) Inhibidores de ssao de aminopirimidina.
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
CR20190354A (es) Compuestos inhibidores del vih
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX2018009175A (es) Agonista fxr derivado de esteroides.
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX2017009449A (es) Inhibidor jak.
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
MX2016008624A (es) Inhibidores de serina/treonina cinasa.
EA201591509A1 (ru) Ингибиторы cdc7
ECSP17054980A (es) Inhibidores selectivos de bace1
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
MX382765B (es) Tratamiento para la colangitis biliar primaria.
EA201692470A1 (ru) Фармацевтические комбинации
SV2016005313A (es) Derivados de carboxamida
UY37941A (es) Derivados de bencimidazol y sus usos
UY36123A (es) Derivados de carboxamida
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias